- Home
- AMSF vs BBOT Comparison
AMSF vs BBOT Comparison
Compare AMSF & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | BBOT |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.5M | 442.6M |
| IPO Year | 1996 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMSF | BBOT |
|---|---|---|
| Price | $19.71 | $2.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $31.00 | $23.55 |
| AVG Volume (30 Days) | 352.0K | ★ 580.0K |
| Earning Date | 10-28-2026 | 11-20-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $2.26 | N/A |
| P/E Ratio | $12.71 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $20.13 | $2.22 |
| 52 Week High | $42.10 | $14.87 |
Technical Indicators
Market Signals| Indicator | AMSF | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 20.53 | 17.66 |
| Support Level | N/A | N/A |
| Resistance Level | $34.15 | $2.95 |
| Average True Range (ATR) | 0.99 | 0.20 |
| MACD | -0.56 | 0.06 |
| Stochastic Oscillator | 6.58 | 0.54 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.